관상동맥 커팅 풍선 시장 : 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the coronary cutting balloon market size is projected to expand from USD 316 million in 2025 and USD 344.12 million in 2026 to USD 527.05 million by 2031, registering a CAGR of 8.90% between 2026 to 2031.

This report is Segmented by Number of Blades (Three Blades, Four Blades), Application (Calcified Lesion Treatment, In-Stent Restenosis, Lesion Preparation, Others), End Use (Hospitals, Catheterization Labs, Ambulatory Surgery Centers, Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Coronary Cutting Balloon Market Trends and Insights

Rising Burden of Heavily Calcified Coronary Lesions

Demand in the coronary cutting balloon market rests on a clear rise in coronary artery calcification across PCI populations. Moderate-to-severe calcification occurs in 18% to 26% of patients presenting for planned PCI, and the burden rises further in patients older than 70 and in those with diabetes, chronic kidney disease, or dyslipidemia. Heavily calcified lesions carried a 27.1% one-year MACE rate, versus 15% in less calcified cohorts, which keeps these lesions near the center of procedural risk planning in the coronary cutting balloon market. Standard non-compliant balloons often fail to create adequate dilation in this setting, so microblade scoring still fills a defined clinical need in complex lesion preparation. The 2024 SCAI expert consensus on calcified coronary lesion management further supported staged lesion-modification protocols, which help standardize use across high-volume centers and keep the coronary cutting balloon market tied closely to complex PCI workflows. As the elderly and diabetic patient base expands, the coronary cutting balloon market should continue to benefit from a durable flow of complex coronary cases that need controlled plaque modification.

Expanding Use in Complex PCI and Lesion Preparation

The coronary cutting balloon market is no longer shaped only by rescue use, because operators are increasingly using these devices as a planned step in complex PCI protocols. The RODIN-CUT technique, described in 2025, presented a structured IVUS-guided sequential inflation method that showed dose-dependent plaque modification and more controlled lesion preparation in moderately calcified vessels. That approach matters for the coronary cutting balloon market because it links device use more closely to repeatable workflows rather than to one-off operator preference. The same shift is visible in combination therapy, where ROTA-CUT data showed mean stent expansion of 86.1% versus 78.6% with non-cutting balloons after atherectomy. This strengthens the role of the coronary cutting balloon market within multistep calcium-management strategies, especially in centers already comfortable with adjunctive technologies and imaging support. As more PCI teams adopt planned lesion preparation instead of late bailout use, the coronary cutting balloon market should see steadier procedural demand and higher device use per complex case

Higher Device Cost Versus Conventional Balloon Platforms

A core limit on the coronary cutting balloon market is the unit-price premium over standard non-compliant balloon platforms. That premium creates procurement friction in cost-sensitive health systems, especially where reimbursement packages do not isolate plaque-modification tools from the broader PCI payment bundle. In hospital outpatient settings, the incremental device cost can move directly into the performing facility margin, which raises substitution pressure when clinical guidance does not clearly require cutting balloon use. The issue is more visible across South Asia, Latin America, and parts of the Middle East and Africa, where formulary budgets remain tight, and public hospital purchasing is more price-driven. The coronary cutting balloon market also faces a wider relative premium when domestic suppliers in China and India reduce the price floor for basic PTCA balloons, because the gap against advanced scoring platforms becomes easier for buyers to see. Regulatory compliance costs in premium markets add another layer of price stickiness, which helps established brands hold premium positioning but slows broader expansion of the coronary cutting balloon market in value-sensitive channels.

Other drivers and restraints analyzed in the detailed report include:

1. Higher Demand for Image-Guided Precision Devices
2. Shift Toward Minimally Invasive Coronary Interventions
3. Competition From Drug-Coated Balloons and Atherectomy Systems

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Three-blade devices held 62.2% of the coronary cutting balloon market share in 2025, supported by their fit across the 2.00 mm to 3.25 mm vessel range that covers much of routine coronary lesion treatment. This part of the coronary cutting balloon industry also benefits from a longer commercial track record, which supports physician familiarity and purchasing confidence in established catheterization programs. Boston Scientific's WOLVERINE platform reflects this sizing logic, because its three-atherotome models serve the 2.00 mm to 3.25 mm range while four-atherotome models are positioned for 3.50 mm to 4.00 mm vessels. That product split shows how blade configuration in the coronary cutting balloon market is tied directly to vessel circumference and contact geometry rather than to a simple brand preference.

The coronary cutting balloon market size for four-blade devices is projected to expand at 10.4% CAGR through 2031, making it the fastest-growing blade configuration. Growth is linked to larger vessel interventions, especially in proximal and mid-left anterior descending artery procedures, where broader plaque contact can support more efficient calcium fracture. The CUPID trial also included four-blade cutting balloon angioplasty in its IVUS-guided arm, which adds formal clinical visibility to this platform within the coronary cutting balloon market. Over time, suppliers that show stronger OCT-measured fracture depth and better procedural control in large-caliber vessels should have a clearer differentiation story in the coronary cutting balloon market.

Complete Report Scope:

• By Number of Blades
  • Three Blades
  • Four Blades
• By Application
  • Calcified Lesion Treatment
  • In-Stent Restenosis
  • Lesion Preparation
  • Other Applications
• By End Use
  • Hospitals
  • Catheterization Laboratories
  • Ambulatory Surgery Centers
  • Other End Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 38.2% of the coronary cutting balloon market share in 2025, which made it the largest regional contributor. The United States drives most of that position through high PCI procedure intensity, broad commercial presence from leading manufacturers, and well-established outpatient reimbursement structures support for ASC reimbursement also strengthens the regional outlook, because outpatient coronary intervention investment remains more economically viable when payment rates move upward North America also remains important to the coronary cutting balloon market because it is a major source of clinical evidence generation and protocol standardization around calcified lesion treatment. Europe is a mature regional base for the coronary cutting balloon market, with Germany standing out because stronger IVUS adoption helps identify more lesions that need controlled plaque modification.

Asia-Pacific is the fastest-growing region in the coronary cutting balloon market, with a projected CAGR of 10.8% through 2031. China is the main growth engine, because the catheterization procedure volume reached 1.91 million in 2024 and is projected to exceed 3.6 million by 2030, creating the largest incremental device demand pool. India adds another growth layer through wider PCI access across private hospital networks, while Japan and South Korea support higher device use per procedure through mature OCT and IVUS-guided PCI protocols. Domestic suppliers such as Lepu Medical are also making the coronary cutting balloon market more price competitive in Asia-Pacific through localized offerings and broader tender participation.

South America, the Middle East and Africa, and the rest of Asia-Pacific represent smaller shares today, but they still matter to the final expansion range of the coronary cutting balloon market. Brazil and Argentina anchor South American demand, while reimbursement inconsistency outside major urban centers continues to slow adoption of specialized lesion-preparation tools. In the Middle East, GCC investment in cardiac catheterization infrastructure is creating a better environment for internationally certified products with stronger clinical support. Across these developing regions, training programs and proctor-led cases remain critical, because operator familiarity still acts as a larger barrier than basic clinical rationale in the coronary cutting balloon market

1. Abbott Laboratories
2. Acrostak
3. B. Braun
4. BIOTRONIK SE and Co. KG
5. Boston Scientific
6. Cardionovum
7. Cook Group
8. Hexacath
9. Johnson & Johnson
10. Lepu Medical
11. Medtronic
12. Merit Medical Systems
13. MicroPort
14. Nipro
15. Shunqi Medical
16. SIS Medical
17. Teleflex
18. Terumo

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Burden of Heavily Calcified Coronary Lesions
  • 4.2.2 Expanding Use in Complex PCI and Lesion Preparation
  • 4.2.3 Higher Demand for Image-Guided Precision Devices
  • 4.2.4 Shift Toward Minimally Invasive Coronary Interventions
  • 4.2.5 Local Manufacturing and Price-Optimized Products in Emerging Asia
  • 4.2.6 Training-Driven Adoption in High-Volume Cath Labs
• 4.3 Market Restraints
  • 4.3.1 Higher Device Cost Versus Conventional Balloon Platforms
  • 4.3.2 Competition From Drug-Coated Balloons and Atherectomy Systems
  • 4.3.3 Procedure Complexity and Operator Learning Curve
  • 4.3.4 Reimbursement Variability Across Cost-Sensitive Markets
• 4.4 Supply Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Number of Blades
  • 5.1.1 Three Blades
  • 5.1.2 Four Blades
• 5.2 By Application
  • 5.2.1 Calcified Lesion Treatment
  • 5.2.2 In-Stent Restenosis
  • 5.2.3 Lesion Preparation
  • 5.2.4 Other Applications
• 5.3 By End Use
  • 5.3.1 Hospitals
  • 5.3.2 Catheterization Laboratories
  • 5.3.3 Ambulatory Surgery Centers
  • 5.3.4 Other End Users
• 5.4 By Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
  • 6.3.1 Abbott Laboratories
  • 6.3.2 Acrostak
  • 6.3.3 B. Braun SE
  • 6.3.4 BIOTRONIK SE and Co. KG
  • 6.3.5 Boston Scientific
  • 6.3.6 Cardionovum GmbH
  • 6.3.7 Cook Medical
  • 6.3.8 Hexacath
  • 6.3.9 Johnson and Johnson
  • 6.3.10 Lepu Medical Technology Co., Ltd.
  • 6.3.11 Medtronic plc
  • 6.3.12 Merit Medical Systems, Inc.
  • 6.3.13 MicroPort Scientific Corporation
  • 6.3.14 Nipro Corporation
  • 6.3.15 Shunqi Medical
  • 6.3.16 SIS Medical
  • 6.3.17 Teleflex Incorporated
  • 6.3.18 Terumo Corporation

7 Market Opportunities & Future Outlook

• 7.1 White-Space and Unmet-Need Assessment